{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:26:21Z","timestamp":1786112781601,"version":"build-2736575974"},"update-to":[{"DOI":"10.1002\/14651858.cd012570","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000}}],"reference-count":49,"publisher":"Wiley","issue":"2","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012570.pub2","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T06:45:14Z","timestamp":1740638714000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Renin inhibitors versus angiotensin receptor blockers for primary hypertension"],"prefix":"10.1002","volume":"2025","author":[{"given":"Gan Mi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacology; School of Pharmacy, Fudan University; Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang Jin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacology; School of Pharmacy, Fudan University; Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linyi","family":"Fan","sequence":"additional","affiliation":[{"name":"Vancouver School of Economics; University of British Columbia; Vancouver Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pharmacology; School of Pharmacy, Fudan University; Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen Lu","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Pharmacology; School of Pharmacy, Fudan University; Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M","family":"Wright","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Pharmacology and Therapeutics; University of British Columbia; Vancouver Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"issue":"4","key":"10.1002\/14651858.CD012570.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1161\/CIRCULATIONAHA.108.826214","article-title":"Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass inpatients with hypertension and left ventricular hypertrophy","volume":"119","author":"Solomon","year":"2009","journal-title":"Circulation"},{"issue":"1","key":"10.1002\/14651858.CD012570.pub2-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/jch.12018","article-title":"Sustained blood pressure-lowering effect of aliskiren compared with telmisartan after a single missed dose","volume":"15","author":"D\u00fcsing","year":"2013","journal-title":"Journal of Clinical Hypertension"},{"issue":"5","key":"10.1002\/14651858.CD012570.pub2-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1097\/HJH.0b013e328351c263","article-title":"Sustained decrease in blood pressure following missed doses of aliskiren or telmisartan: the ASSERTIVE double-blind, randomized study","volume":"30","author":"D\u00fcsing","year":"2012","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD012570.pub2-BIB0004|cit4","unstructured":"A randomized, double-blind, placebo and active-controlled, multicenter, parallel-group study comparing SPP100 (Aliskiren) 150 mg to placebo and to Losartan 50 mg to evaluate efficacy, safety and pharmacokinetics in patients with mild to moderate essential hypertension https:\/\/www.novctrd.com"},{"issue":"12","key":"10.1002\/14651858.CD012570.pub2-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1055\/s-0030-1263123","article-title":"Different effects of aliskiren and losartan on fibrinolysis and insulin sensitivity in hypertensive patients with metabolic syndrome","volume":"42","author":"Fogari","year":"2010","journal-title":"Hormone and Metabolic Research"},{"issue":"8","key":"10.1002\/14651858.CD012570.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1161\/01.CIR.0000156466.02908.ED","article-title":"Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients","volume":"111","author":"Gradman","year":"2005","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD012570.pub2-BIB0007|cit7","unstructured":"A randomized, double-blind, double-dummy, parallel-group study to compare the effects of multiple dose administration of aliskiren and irbesartan on biomarkers of inflammation and cardiovascular risk in patients with hypertension and metabolic syndrome https:\/\/clinicaltrialsregister.eu"},{"issue":"3","key":"10.1002\/14651858.CD012570.pub2-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/jhh.2010.38","article-title":"Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome","volume":"25","author":"Krone","year":"2011","journal-title":"Journal of Human Hypertension"},{"issue":"9583","key":"10.1002\/14651858.CD012570.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0140-6736(07)61124-6","article-title":"Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial","volume":"370","author":"Oparil","year":"2007","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012570.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1007\/s12325-008-0123-x","article-title":"Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study","volume":"25","author":"Yarows","year":"2008","journal-title":"Advances in Therapy"},{"issue":"2","key":"10.1002\/14651858.CD012570.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/jhh.2009.38","article-title":"Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study","volume":"24","author":"Palatini","year":"2009","journal-title":"Journal of Human Hypertension"},{"issue":"1","key":"10.1002\/14651858.CD012570.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.amjhyper.2006.06.003","article-title":"Aliskiren, an orally effective renin inhibitor,provides antihypertensive efficacy alone and in combination with valsartan","volume":"20","author":"Pool","year":"2007","journal-title":"American Journal of Hypertension"},{"issue":"6","key":"10.1002\/14651858.CD012570.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1161\/01.HYP.0000101688.17370.87","article-title":"Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren","volume":"42","author":"Stanton","year":"2003","journal-title":"Hypertension"},{"issue":"1","key":"10.1002\/14651858.CD012570.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1177\/1470320312454766","article-title":"Blood pressure and plasma renin activity responses to different strategies to inhibit the renin-angiotensin-aldosterone system during exercise","volume":"14","author":"Williams","year":"2013","journal-title":"Journal of the Renin-Angiotensin-Aldosterone System"},{"issue":"6","key":"10.1002\/14651858.CD012570.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/07853890.2017.1313447","article-title":"Effects of direct renin inhibition versus angiotensin II receptor blockade on angiotensin profiles in non-diabetic chronic kidney disease","volume":"49","author":"Antlanger","year":"2017","journal-title":"Annals of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012570.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1161\/HYPERTENSIONAHA.114.03380","article-title":"Effects of a long-term treatment with aliskiren or ramipril on structural alterations of subcutaneous small-resistance arteries of diabetic hypertensive patients","volume":"64","author":"De Ciuceis","year":"2014","journal-title":"Hypertension"},{"issue":"5","key":"10.1002\/14651858.CD012570.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/jhh.2014.86","article-title":"The impact of age on the benefits and risks of aliskiren treatment: analyses of the 3A registry","volume":"29","author":"Friedrich","year":"2015","journal-title":"Journal of Human Hypertension"},{"issue":"3","key":"10.1002\/14651858.CD012570.pub2-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"354","DOI":"10.2215\/CJN.07720618","article-title":"Efficacy and safety of imarikiren in patients with Type 2 diabetes and microalbuminuria. A randomized, controlled trial","volume":"14","author":"Ito","year":"2019","journal-title":"Clinical Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD012570.pub2-BIB0019|cit19","unstructured":"A clinical study to compare the safety and efficacy of an aliskiren-based regimen with a lisinopril based regimen in patients with severe hypertension https:\/\/clinicaltrials.gov\/study\/NCT00219050?term=NCT00219050&rank=1"},{"issue":"9","key":"10.1002\/14651858.CD012570.pub2-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1093\/ndt\/gfq857","article-title":"Aliskiren reduces sympathetic nerve activity and blood pressure in chronic kidney disease patients","volume":"26","author":"Siddiqi","year":"2010","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD012570.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1080\/10641963.2016.1200064","article-title":"Comparison of direct renin inhibitor and angiotensin II receptor blocker on clinicand ambulatory blood pressure profiles in hypertension with chronic kidney disease","volume":"38","author":"Uneda","year":"2016","journal-title":"Clinical and Experimental Hypertension"},{"issue":"4","key":"10.1002\/14651858.CD012570.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1177\/1470320313510584","article-title":"Aliskiren and losartan trial in non-diabetic chronic kidney disease","volume":"15","author":"Woo","year":"2014","journal-title":"Journal of the Renin-Angiotensin-Aldosterone System"},{"issue":"23","key":"10.1002\/14651858.CD012570.pub2-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for Type 2 diabetes","volume":"367","author":"Parving","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012570.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"106","DOI":"10.2174\/1389450115666140211113040","article-title":"Efficacy and safety profile of aliskiren: practical implications for clinicians","volume":"9","author":"Angeli","year":"2014","journal-title":"Current Drug Safety"},{"issue":"11","key":"10.1002\/14651858.CD012570.pub2-BIB0025|cit25","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008170.pub3","article-title":"First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension","author":"Chen","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD012570.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.cjca.2014.02.002","article-title":"The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension","volume":"30","author":"Dasgupta","year":"2014","journal-title":"Canadian Journal of Cardiology"},{"key":"10.1002\/14651858.CD012570.pub2-BIB0027|cit27","unstructured":"Deeks JJ Altman DG Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from https:\/\/training.cochrane.org\/handbook\/archive\/v5.1\/"},{"issue":"20","key":"10.1002\/14651858.CD012570.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1161\/CIRCULATIONAHA.113.007699","article-title":"Closing the gap in hypertension control between younger and older adults: National Health and Nutrition Examination Survey (NHANES) 1988 to 2010","volume":"129","author":"Egan","year":"2014","journal-title":"Circulation"},{"issue":"38","key":"10.1002\/14651858.CD012570.pub2-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC Guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD012570.pub2-BIB0030|cit30","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2023"},{"issue":"4","key":"10.1002\/14651858.CD012570.pub2-BIB0031|cit31","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003822.pub2","article-title":"Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension","author":"Heran","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012570.pub2-BIB0032|cit32","unstructured":"Higgins JP Green S Cochrane Handbook for SystematicReviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from https:\/\/training.cochrane.org\/handbook\/archive\/v5.1\/"},{"issue":"5","key":"10.1002\/14651858.CD012570.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1440-1797.2006.00665.x","article-title":"Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy","volume":"11","author":"Horita","year":"2006","journal-title":"Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD012570.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC8)","volume":"311","author":"James","year":"2014","journal-title":"Journal of the American Medical Association"},{"issue":"8","key":"10.1002\/14651858.CD012570.pub2-BIB0035|cit35","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009096.pub2","article-title":"Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension","author":"Li","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9311","key":"10.1002\/14651858.CD012570.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpointreduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahl\u00f6f","year":"2002","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD012570.pub2-BIB0037|cit37","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007066.pub2","article-title":"Blood pressure lowering efficacy of renin inhibitors for primary hypertension","author":"Musini","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10304","key":"10.1002\/14651858.CD012570.pub2-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(21)01330-1","article-title":"Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants","volume":"398","author":"NCD Risk Factor Collaboration (NCD-RisC)","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD012570.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/01.HYP.0000253780.36691.4f","article-title":"Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker","volume":"49","author":"O'Brien","year":"2007","journal-title":"Hypertension"},{"key":"10.1002\/14651858.CD012570.pub2-BIB0040|cit40","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2024"},{"key":"10.1002\/14651858.CD012570.pub2-BIB0041|cit41","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and \u2019Summary of findings\u2019 tables. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from https:\/\/training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.CD012570.pub2-BIB0042|cit42","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JP Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from https:\/\/training.cochrane.org\/handbook\/archive\/v5.1\/"},{"issue":"9426","key":"10.1002\/14651858.CD012570.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","article-title":"Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial","volume":"363","author":"Julius","year":"2004","journal-title":"Lancet"},{"issue":"10","key":"10.1002\/14651858.CD012570.pub2-BIB0044|cit44","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012569.pub2","article-title":"Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension","author":"Wang","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD012570.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jash.2007.04.004","article-title":"Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis","volume":"1","author":"Weir","year":"2007","journal-title":"Journal of the American Society of Hypertension"},{"issue":"10","key":"10.1002\/14651858.CD012570.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/j.1751-7176.2010.00352.x","article-title":"Safety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in more than 12,000 patients with hypertension","volume":"12","author":"White","year":"2010","journal-title":"Journal of Clinical Hypertension"},{"key":"10.1002\/14651858.CD012570.pub2-BIB0047|cit47","unstructured":"World Health Organization (WHO) Guideline for the pharmacological treatment of hypertension in adults; August 2021 Available from https:\/\/www.who.int\/publications\/i\/item\/9789240033986"},{"issue":"2","key":"10.1002\/14651858.CD012570.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1177\/1470320310381912","article-title":"A systematic review and meta-analysis of aliskiren and angiotension receptor blockers in the management of essential hypertension","volume":"12","year":"2011","journal-title":"Journal of the Renin-Angiotensin-Aldosterone System"},{"issue":"2","key":"10.1002\/14651858.CD012570.pub2-BIB0049|cit49","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012570","article-title":"Renin inhibitors versus angiotensin receptor blockers for primary hypertension.","author":"Li","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T15:48:05Z","timestamp":1785944885000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012570.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":49,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012570.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]}}}